Conquering the final frontier in lung transplantation - Mesenchymal stromal cell therapy for chronic lung allograft dysfunction

征服肺移植的最后前沿——间充质基质细胞治疗慢性同种异体肺移植功能障碍

• 批准号: nhmrc : GNT1103789
• 负责人: A/Pr Glen Westall
• 金额: $ 188.78万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/conquering-final-frontier-allograft-dysfunction/1346305
• 关键词: Conquering; final; frontier; lung; transplantation

Lung transplantation remains the only treatment option for an increasing number of Australians with end-stage lung disease, however long-term outcomes are severely compromised by the almost universal development of chronic rejection. Mesenchymal stromal cells (MSCs) hold great promise in treating rejection, and in a world-first we have recently demonstrated that this approach is safe. In another world-first, this randomized, controlled study will determine whether MSC therapy is effective.

对于越来越多的患有终末期肺部疾病的澳大利亚人来说，肺移植仍然是唯一的治疗选择，但慢性排斥反应的几乎普遍发展严重影响了长期结果。间充质基质细胞(MSCs)在治疗排斥反应方面前景看好，最近我们在世界上第一次证明了这种方法是安全的。在另一个世界第一，这项随机对照研究将确定MSC疗法是否有效。